ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
15 announcements with these filters
Vivo Bio Tech Ltd reported revenue from operations of ₹17.2 Cr (+31.3% YoY) and net profit of ₹1.1 Cr (+22.2% YoY) for Q2 FY27.
Vivo Bio Tech has scheduled a board meeting for November 11, 2026, to consider unaudited standalone and consolidated results for the quarter ended September 30, 2026. The trading window stays closed until 48 hours after results declaration.
The company submitted its periodic shareholding pattern for the quarter ended September 30, 2026, disclosing its promoter and public shareholding as mandated by SEBI.
Vivo Bio Tech reports a fire at its Telangana research facility damaging labs, equipment, and samples. No casualties; damage under assessment with adequate insurance coverage in place.
Vivo Bio Tech Ltd filed its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018.
Vivo Bio Tech Limited announced the re-appointment of Sri Kalyan Kompella and Sankaranarayanan Alangudi as Executive Directors, effective November 2026 and January 2027 respectively.
Vivo Bio Tech Ltd held its 39th Annual General Meeting on September 30, 2026, to adopt financial statements and re-appoint directors.
Vivo Bio Tech has sent letters to shareholders without registered email addresses, providing a web-link to access the Annual Report for the financial year 2025-26.
Vivo Bio Tech Limited has submitted its Annual Report for the financial year 2025-2026 along with the notice for its 39th Annual General Meeting.
Vivo Bio Tech Ltd issued a notice for its 39th Annual General Meeting to be held on September 30, 2026, via video conferencing.
P.K.L Solution Private Limited, a promoter group entity, sold 6,00,000 equity shares of Vivo Bio Tech Limited. This off-market transaction reduced their stake to nil.
Vivo Bio Tech Limited announced the re-appointment of Mr. Sri Kalyan Kompella and Mr. Sankaranarayanan Alangudi as Executive Directors of the company.
Vivo Bio Tech's board meeting approved the 39th AGM date and the re-appointment of three Whole-Time Directors.
Vivo Bio Tech Limited announced that 8,10,000 promoter-allotted warrants have expired due to non-exercise within the 18-month tenure.
Vivo Bio Tech Limited announced that 483 outstanding convertible equity warrants have expired due to non-exercise within the eighteen-month tenure.